Chemcrux Enterprises Q1 FY27 Standalone Profit Rises 135%

Chemcrux Enterprises reported standalone net profit of ₹1.37 crore for the quarter ended June 30, 2026, up 135.1% year on year, as revenue from operations rose 31.0% to ₹21.94 crore. The Vadodara-based bulk drug intermediate manufacturer also reported higher consolidated revenue and profit, with the board approving the unaudited results on August 4, 2026.

What did Chemcrux Enterprises report for Q1 FY27?

Chemcrux Enterprises recorded standalone revenue from operations of ₹21.94 crore in Q1 FY27, compared with ₹16.75 crore in the corresponding quarter of FY26. Standalone profit before tax rose 153.3% to ₹1.85 crore from ₹0.73 crore, while net profit after tax increased to ₹1.37 crore from ₹0.58 crore.

On a consolidated basis, revenue from operations was ₹21.94 crore, against ₹16.50 crore a year earlier. Consolidated profit before tax rose to ₹0.98 crore from ₹0.03 crore, and consolidated net profit attributable to owners increased to ₹0.51 crore from ₹0.09 crore. The disclosed consolidated figures include wholly owned subsidiary Kalichem Private Limited.

The reported standalone earnings per share rose to ₹0.93 in Q1 FY27 from ₹0.39 in Q1 FY26. Consolidated earnings per share increased to ₹0.34 from ₹0.06. Total comprehensive income was ₹1.59 crore on a standalone basis and ₹0.72 crore on a consolidated basis.

How were Chemcrux Enterprises results approved?

Chemcrux Enterprises' board of directors approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, on August 4, 2026. The results were accompanied by a Limited Review Report from the company's statutory auditors, Naresh & Co., Chartered Accountants.

The company had also issued a board meeting intimation for considering unaudited financial results for the quarter and half year ended September 30, 2026. This disclosure indicates that the next set of quarterly financial results was scheduled for board consideration, along with other related matters and any other business on the agenda.

Earlier disclosures show that the board had approved unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025, after review and recommendation by the Audit Committee. Chemcrux Enterprises subsequently published the financial results in newspapers under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements regulations.

Which Q1 FY27 financial metrics changed the most?

Chemcrux Enterprises' largest reported percentage increase was in consolidated profit before tax, which rose 3,073.8% year on year from ₹0.03 crore to ₹0.98 crore. The percentage is based on a low base in Q1 FY26, while the absolute increase was ₹0.95 crore.

Standalone net profit rose by ₹0.79 crore to ₹1.37 crore, and standalone revenue increased by ₹5.19 crore. Consolidated net profit increased by ₹0.41 crore to ₹0.51 crore. These figures show that both standalone and consolidated operations reported higher revenue and profit compared with the corresponding quarter a year earlier.

How do the latest results compare with recent quarters?

Chemcrux Enterprises reported net sales turnover of ₹21.94 crore in the June 2026 quarter, compared with ₹24.28 crore in the March 2026 quarter and ₹22.11 crore in the December 2025 quarter. Operating profit was ₹2.70 crore in June 2026, below ₹4.19 crore in March 2026 but above ₹1.63 crore in June 2025 in the quarterly-results data.

The quarterly-results series also showed reported profit after tax of ₹0.51 crore for June 2026, ₹1.85 crore for March 2026, ₹1.58 crore for December 2025, ₹0.21 crore for September 2025 and ₹0.09 crore for June 2025. The separately disclosed Q1 FY27 financial-results announcement reported standalone and consolidated figures and should be read on the basis presented in that filing.

The company's sales have varied across the recent quarters, ranging from ₹15.72 crore in March 2025 to ₹24.28 crore in March 2026 in the provided quarterly data. The Q1 FY27 standalone revenue of ₹21.94 crore was higher than the year-earlier level but below the immediately preceding March-quarter sales figure.

What do the results mean for investors and operations?

Chemcrux Enterprises' Q1 FY27 disclosures show year-on-year growth in revenue, profit before tax and net profit in both standalone and consolidated statements. For investors, the key reported measures are the 31.0% increase in standalone revenue and the 135.1% increase in standalone net profit, along with the rise in earnings per share to ₹0.93.

The difference between standalone and consolidated profit is relevant because the consolidated statements include Kalichem Private Limited. While standalone net profit was ₹1.37 crore, consolidated net profit attributable to owners was ₹0.51 crore. The disclosures do not provide a separate explanation for the difference, so the financial statements and accompanying notes remain the primary source for assessing subsidiary-level effects.

For industry observers, Chemcrux Enterprises operates in bulk drug intermediates, where quarterly performance can be assessed through changes in sales, operating profit, pre-tax profit and net profit. The company has disclosed the results as unaudited and subject to limited review, which is the stated basis for the Q1 FY27 figures.

Conclusion

Chemcrux Enterprises delivered higher Q1 FY27 revenue and profitability compared with the corresponding quarter of FY26. Standalone revenue reached ₹21.94 crore and standalone net profit reached ₹1.37 crore, while consolidated revenue was also ₹21.94 crore and consolidated net profit was ₹0.51 crore. The results were approved by the board on August 4, 2026 following limited review by the statutory auditors.

The next disclosed financial milestone is the board's consideration of unaudited results for the quarter and half year ended September 30, 2026. Investors will watch the subsequent filing for updated sales, operating-profit and profit figures, as well as any disclosures related to the company's consolidated operations and Kalichem Private Limited.